Mitochondrial

MOTS-c

Mitochondrial ORF of the 12S rRNA Type-c

16-aa mitochondrial ORF peptide (MDP). Lee 2015 AMPK/metabolic papers are real. Not metformin, not an obesity RCT, not exercise in a vial. Community mg schedules are scaled from rodents, not a label.

Not FDA-approved - research chemical
Reviewed by CalcMyPeptide Editorial Team
Last updated: August 2026Evidence: Low3 peer-reviewed citations
Typical research dose
5-10 mg/week
Frequency
3-5× weekly
Half-life
~16 hours
Common vials
5 mg / 10 mg
CAS
1448498-38-3
Molecular weight
~2174 Da

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Metabolic / weight3.5/10

    Lee 2015 (PMID 25738459) is Cell Metabolism: circulating MOTS-c, AMPK, mouse metabolic work. Not an obesity RCT. Community/small-human ceiling after haircut: 3.5.

  • Longevity / aging2/10

    Mitokine story. Lifespan headlines are preclinical. Mechanism band.

Compound card

Sequence
MRWQEMGYIFYPRKLR
Class
Mitochondrial ORF peptide (16 aa; MDP)
Formula
MTNIRTLSRS... (16 aa mitochondrial peptide)
Status
Not FDA-approved · research use
Dose it
5 mg + 2 mL BAC water → 2.5 mg/mL · 5000 mcg ≈ 200 units (U-100)
Open in calculator

How it works

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a mitochondrial-derived peptide (MDP) - a signaling molecule encoded in the mitochondrial genome rather than the nuclear genome. It activates the AMPK pathway, the master metabolic regulator that enhances cellular energy metabolism, improves insulin sensitivity, and promotes glucose uptake in skeletal muscle.

MOTS-c represents a new class of signaling molecules called "mitokines" - mitochondrial hormones that communicate metabolic status from mitochondria to the nucleus and distant tissues. It has shown exercise-mimetic effects, improving metabolic health and physical performance in animal models.

Source: PMID: 25738459

Goal context

Exercise mimetic is a paper genre

AMPK activation in mice is not a VO2max trial. Train anyway.

Background & History

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, discovered by Changhan David Lee at USC in 2015 (Cell Metabolism). It was the first regulatory peptide found to be encoded in mitochondrial DNA rather than nuclear DNA - a paradigm shift in mitochondrial biology. MOTS-c acts as a retrograde signal from mitochondria to the nucleus, activating AMPK and regulating metabolic gene expression. Exercise increases circulating MOTS-c levels, suggesting it mediates some of the metabolic benefits of physical activity.

Research Use Cases

  • ✓Identity: 16-aa mtDNA ORF vs MOTS-c marketing
  • ✓AMPK papers vs an obesity RCT (there is not one)
  • ✓Not metformin and not an exercise replacement

Dosing

PhaseDoseFrequencyNotes
Standard Protocol5 - 10 mg3-5x per week (SC)16-hour half-life supports intermittent dosing. Most rodent research used 5 mg/kg.

Administration

Route / form
Subcutaneous injection
Timing
Morning or pre-exercise. Fasting not required.
Empty stomach?
No - Food timing is not critical.

Timeline

Week 1-4
Improved energy levels and insulin sensitivity. Exercise performance enhancement reported.
Month 1-3
Body composition improvements. Metabolic health markers may improve.

Who it is for

Metabolic Optimization

Moderate

AMPK activation improves glucose metabolism and insulin sensitivity. Exercise-mimetic properties.

Longevity / Anti-Aging

Low

Promising mitokine signaling in animal models. Human data is very limited.

Reconstitution

VialWaterConcentrationExample dose
5 mg lyophilized2 mL BAC2.5 mg/mL5 mg / 2 mL = 2.5 mg/mL. 5 mg = 2.0 mL = 200 units. Split across the week; do not treat rodent mg/kg as a human label.

Change vial size or water volume? Open the reconstitution calculator.

Safety & Considerations

Research peptide. Limited human safety data - primarily rodent models. Naturally occurring endogenous mitochondrial peptide. Monitor blood glucose if diabetic.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • Rodent mg/kg does not become 5–10 mg three times a week as a fact. That is community scaling.
  • Half-life figures on vendor cards are estimates. Human PK is thin.
  • This site will not treat diabetes or obesity from a MOTS-c page.

Human evidence

Low · mitokine papers, thin human PK

  • Lee 2015 and related MDP work are metabolic/animal-heavy; not an obesity or diabetes RCT label.
  • Human PK is thin. Vendor half-life cards are estimates.
  • Rodent mg/kg does not become a sourced human titration chart.

Verdict

MOTS-c is a 16-aa peptide encoded in mtDNA. AMPK-linked metabolic papers exist. It is not an exercise-in-a-vial drug, not metformin, and not a type-2-diabetes indication.

Interactions & Contraindications

Research compound - limited human safety data. AMPK activation may interact with metformin (additive effects on glucose metabolism). Caution with insulin or GLP-1 agonists due to additive insulin sensitization. Available in injectable form; oral bioavailability very limited.

Synergies & Common Stacks

Both are mitochondrial-derived peptides (MDPs) with overlapping cytoprotective effects. Humanin protects against apoptosis; MOTS-c enhances metabolic function. Often combined in mitochondrial health protocols.

NAD+ is a cofactor. MOTS-c is an mtDNA ORF with AMPK papers. Complementary marketing is not a mitochondrial-resilience RCT.

Frequently Asked Questions

What does MOTS-c do?▼
MOTS-c activates AMPK to improve energy metabolism, insulin sensitivity, and glucose uptake. Acts as an exercise mimetic producing metabolic benefits similar to physical training.
How is MOTS-c dosed?▼
5-10 mg subcutaneously, 3-5x per week. 16-hour half-life supports intermittent dosing.

References

  1. Reynolds JC et al. “"MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline".” Nature Communications (2021). PMID: 33594076
  2. Reynolds JC, et al. “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline.” Nat Commun (2021). PMID: 33479227
  3. Lee C, et al. “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis.” Cell Metab (2015). PMID: 25738456

📚 Related Articles

Recommended source10% OFF

Get MOTS-c from our recommended source - independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.

Affiliate link · Full review